4CMenB Vaccination Effective Against Invasive Meningococcal Disease in Children Under 5

Vaccine effectiveness with at least one dose was 64 percent against serogroup B, 82 percent against non-serogroup B disease

child vaccine
Adobe Stock

THURSDAY, Feb. 2, 2023 (HealthDay News) -- Complete vaccination with the four-component, protein-based meningococcal serogroup B vaccine (4CMenB) is effective for preventing invasive meningococcal disease in children younger than 5 years, according to a study published in the Feb. 2 issue of the New England Journal of Medicine.

Jesús Castilla, M.D., Ph.D., from the Instituto de Salud Pública de Navarra in Pamplona, Spain, and colleagues examined the effectiveness of 4CMenB in preventing invasive meningococcal disease in children in a nationwide matched case-control study. All laboratory-confirmed cases of invasive meningococcal disease in children younger than 60 months between Oct. 5, 2015, and Oct. 6, 2019, were identified; 306 cases (79.4 percent with serogroup B disease) were matched to 1,224 controls.

The researchers found that 11.4 and 24.3 percent of case patients and controls, respectively, had received at least one dose of 4CMenB. The effectiveness against invasive meningococcal disease caused by any serogroup was 76 percent for complete vaccination (receipt of at least two doses) and 54 percent for partial vaccination. The effectiveness against meningococcal serogroup B disease was 71 percent for complete vaccination. Vaccine effectiveness with at least one dose of 4CMenB was 64 and 82 percent against serogroup B disease and non-serogroup B disease, respectively. Forty-four case patients had serogroup B strains that were expected to be covered by 4CMenB; none of these patients had been vaccinated.

"This evidence may be useful in making decisions about the inclusion of this vaccine in the immunization program of countries where invasive meningococcal disease in children is problematic and its prevention a priority," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Elana Gotkine

Elana Gotkine

Medically reviewed by Mark Arredondo, M.D.

Published on February 02, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ